| Name | Title | Contact Details |
|---|---|---|
Geoffrey Gilmore |
Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary | Profile |
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
Bio Direct is a Taunton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthChem Contract Services is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headcan is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.